Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711344 | 0.88 | ADORA2A (0.67) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL20711215 | 0.87 | DPP4 (0.58) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL20711307 | 0.87 | ADORA3 (0.67) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL20711321 | 0.84 | ADORA2A (0.53) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL20711332 | 0.83 | ADORA2A (0.58) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL20711287 | 0.82 | IMPDH2 (0.52) | IMPDH2IMPDH1ADORA2AADORA2B | |
| SCHEMBL20711221 | 0.81 | DPP4 (0.56) | — | |
| SCHEMBL20711334 | 0.81 | RNMT (0.55) | ADORA2AADORA2B | |
| SCHEMBL22837893 | 0.80 | TRPM2 (0.58) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL20711233 | 0.80 | TRPM2 (0.58) | ADORA2AADORA2BADORA1ADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | IMPDH2 150/4885IMPDH1 69/4885ADORA2A 5/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | IMPDH2 150/4885IMPDH1 69/4885ADORA2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.